Recent reports show that pharmacological activation of a second KDT501 target, AGTR2, in combination with PPARγ activation, ameliorates insulin resistance and reverses β-cell damage in diabetic pancreatic tissue in T2D mice [34]. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.